These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 10224385

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Genetic engineering of recombinant hypoallergenic oligomers of the major birch pollen allergen, Bet v 1: candidates for specific immunotherapy.
    Vrtala S, Hirtenlehner K, Susani M, Hufnagl P, Binder BR, Vangelista L, Pastore A, Sperr WR, Valent P, Ebner C, Kraft D, Valenta R.
    Int Arch Allergy Immunol; 1999; 118(2-4):218-9. PubMed ID: 10224386
    [No Abstract] [Full Text] [Related]

  • 3. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
    Gafvelin G, Thunberg S, Kronqvist M, Grönlund H, Grönneberg R, Troye-Blomberg M, Akdis M, Fiebig H, Purohit A, Horak F, Reisinger J, Niederberger V, Akdis CA, Cromwell O, Pauli G, Valenta R, van Hage M.
    Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Designing hypoallergenic derivatives for allergy treatment by means of in silico mutation and screening.
    Thalhamer T, Dobias H, Stepanoska T, Pröll M, Stutz H, Dissertori O, Lackner P, Ferreira F, Wallner M, Thalhamer J, Hartl A.
    J Allergy Clin Immunol; 2010 Apr; 125(4):926-934.e10. PubMed ID: 20371399
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical testing of recombinant allergens of the mold Alternaria alternata.
    Unger A, Stöger P, Simon-Nobbe B, Susani M, Crameri R, Ebner C, Hintner H, Breitenbach M.
    Int Arch Allergy Immunol; 1999 Apr; 118(2-4):220-1. PubMed ID: 10224387
    [No Abstract] [Full Text] [Related]

  • 8. Clinical trials with recombinant allergens--three perspectives: industry.
    Narkus A, Kniest F, Menzel A, Meyer H, Sprung V.
    Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009 Apr; 96():270-5; discussion 275-8. PubMed ID: 20799471
    [No Abstract] [Full Text] [Related]

  • 9. The current state of recombinant allergens for immunotherapy.
    Pauli G, Malling HJ.
    Curr Opin Allergy Clin Immunol; 2010 Dec; 10(6):575-81. PubMed ID: 20859201
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The importance of recombinant allergens for diagnosis and therapy of IgE-mediated allergies.
    Kraft D, Ferreira F, Vrtala S, Breiteneder H, Ebner C, Valenta R, Susani M, Breitenbach M, Scheiner O.
    Int Arch Allergy Immunol; 1999 Dec; 118(2-4):171-6. PubMed ID: 10224369
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Genetic engineering of allergens: future therapeutic products.
    Ferreira F, Wallner M, Breiteneder H, Hartl A, Thalhamer J, Ebner C.
    Int Arch Allergy Immunol; 2002 Jul; 128(3):171-8. PubMed ID: 12119498
    [Abstract] [Full Text] [Related]

  • 14. Specific immunotherapy, one century later.
    Passalacqua G, Bush RK.
    Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):551-3. PubMed ID: 21971328
    [No Abstract] [Full Text] [Related]

  • 15. Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic asthma in a murine model.
    Siebeneicher S, Reuter S, Wangorsch A, Krause M, Foetisch K, Heinz A, Naito S, Reuter A, Taube C, Vieths S, Scheurer S, Toda M.
    Allergy; 2015 Dec; 70(12):1559-68. PubMed ID: 26304061
    [Abstract] [Full Text] [Related]

  • 16. Engineering allergens.
    Mutschlechner S, Ferreira F.
    Eur Ann Allergy Clin Immunol; 2006 Sep; 38(7):226-9. PubMed ID: 17124778
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients.
    Nopp A, Halldén G, Lundahl J, Johansson E, Vrtala S, Valenta R, Grönneberg R, Van Hage-Hamsten M.
    J Allergy Clin Immunol; 2000 Jul; 106(1 Pt 1):101-9. PubMed ID: 10887312
    [Abstract] [Full Text] [Related]

  • 18. Synthetic and genetically engineered allergen derivatives for specific immunotherapy of type I allergy.
    Valenta R, Vrtala S, Focke-Tejkl M, Twardosz A, Swoboda I, Bugajska-Schretter A, Spitzauer S, Kraft D.
    Clin Allergy Immunol; 2002 Jul; 16():495-517. PubMed ID: 11577556
    [No Abstract] [Full Text] [Related]

  • 19. [Interests of recombinant allergens in the practice of allergy].
    Karoui O, Leimgruber A, Spertini F.
    Rev Med Suisse; 2013 Jan 09; 9(368):22-7. PubMed ID: 23367699
    [Abstract] [Full Text] [Related]

  • 20. Peanut hypersensitivity. IgE binding characteristics of a recombinant Ara h I protein.
    Stanley JS, Helm RM, Cockrell G, Burks AW, Bannon GA.
    Adv Exp Med Biol; 1996 Jan 09; 409():213-6. PubMed ID: 9095243
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.